Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib

Carcinogenesis

Volumn 33, Issue 9, 2012, Pages 1639-1646

  Kirane, Amanda ^a,b   Toombs, Jason E ^a,b   Larsen, Jill E ^b   Ostapoff, Katherine T ^a,b   Meshaw, Kathryn R ^c   Zaknoen, Sara ^d   Brekken, Rolf A ^a,b   Burrows, Francis J ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

^d Tragara Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRICOXIB; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; COLON CARCINOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MONOLAYER CULTURE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HT29 CELLS; HUMANS; MICE; MICE, NUDE; PYRROLES; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865539644     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs195     Document Type: Article

References (48)

1. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
2. Sobolewski, C. et al. (2010) The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int. J. Cell Biol., Article ID 215158.
3. Wang, D. et al. (2010) Eicosanoids and cancer. Nat. Rev. Cancer, 3, 181-193
4. De Groot, D.J. et al. (2007) Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit. Rev. Oncol. Hematol., 61, 52-69.
5. Park, S.W. et al. (2011) The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2 on the proliferation of colon cancer cells. J. Pharm. Exper. Therap., 336, 516-523.
6. Méric, J.B. et al. (2006) Cyclooxygenase-2 as a target for anticancer drug development. Crit. Rev. Onc./Hem., 59, 51-64.
7. Krysan, K. et al. (2005) Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res., 65, 6275-6281.
8. Wang, D. et al. (2005) Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein. Cancer Res., 65, 1822-1829.
9. Castellone, M.D. et al. (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science, 310, 1504-1510.
10. Chen, W. et al. (2010) Acquired activation of the Akt/cyclooxygenase-2/ Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol. Pharm., 77, 416-423.
11. Williams, C.S. et al. (2000) Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res., 60, 6045-6051.
12. Trifan, O.C. et al. (2002) Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res., 62, 5778-5784.
13. Schiffmann, S. et al. (2008) The anti-proliferative potency of celecoxib in not a class effect of coxibs. Biochem. Pharm., 76, 179-187.
14. Kazanov, D. et al. (2004) Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. Clin Cancer Res., 10, 267-271.
15. Paulson, S.K. et al. (2001) Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J. Pharm. Exp. Ther., 297, 638-645.
16. Arico, S. et al. (2002) Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer. J. Biol. Chem., 277, 27613-27621.
17. http://clinicaltrials.gov/ct2/results?term=apricoxib
18. Ushiyama, S. et al. (2008) Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. Eur. J. Pharm., 578, 76-86.
19. Senzaki, M. et al. (2008) CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents. Int. J. Cancer, 122, 1384-1390.
20. Reckamp, K. et al. (2011) Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced non small cell lung cancer. Cancer, 117, 809-818.
21. Dohadwala, M. et al. (2006) Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E2 induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res., 66, 5338-5345.
22. Doherty, G.A. et al. (2009) Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. BMC Cancer, 9, 207-239.
23. Narayanan, B.A. et al. (2003) Suppression of N-methyl-N-nitrosourea/ testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res., 9, 3505-3513.
24. Wild, R.P. et al. (2006) Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol. Cancer Ther., 324, 104-113.
25. Takeyama, Y. et al. (2010) Knockdown of ZEB1, a master epithelial-tomesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Cancer Lett., 296, 216-224.
26. Gotoh, N. et al. (2007) An in vitro model of posterior capsular opacity: SPARC and TGF-beta2 minimize epithelial-to-mesenchymal transition in lens epithelium. Invest Ophthalmol. Vis. Sci., 48, 4679-4687.
27. Reinmuth, N. et al. (2002) Blockade of insulin-like growth factor 1 receptor function inhibits growth and angiogenesis of colon cancer. Clin. Cancer Res., 8, 3259-3269.
28. Jang, T.J. et al. (2009) Cycloxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers. Yonsei Med. J., 50, 818-824.
29. Wellner, U. et al. (2009) The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nature Cell Biol., 11, 1487-1495.
30. Ricci-Vitiani, L. et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature, 445, 111-115.
31. Investigator's Brochure. Investigational Product: Apricoxib Tablets. Tragara Pharmaceuticals 2008.
32. Kaidi, A. et al. (2006) Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res., 66, 6683-6691.
33. Grösch, S. et al. (2006) Cyclooxygenase-2 (COX-2) - independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst., 98, 736-747.
34. Goel, S. et al. (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev., 91, 1071-1121.
35. Wagemakers, M. et al. (2009) COX-2 inhibition combined with radiation reduces orthotopic glioma outgrowth by targeting the tumor vasculature. Translat. Oncol., 2, 1-7.
36. Kalluri, R. et al. (2009) The basics of epithelial-mesenchymal transition. J. Clin. Invest., 119, 1420-1428.
37. Krysan, K. et al. (2008) Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J. Thorac. Oncol., 3, 107-110.
38. Neil, J.R. et al. (2008) Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-ß through a PGE2-dependent mechanisms. Carcinogenesis, 29, 2227-2235.
39. Singh, A. et al. (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 29, 4741-4751.
40. Goessling, W. et al. (2009) Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell, 136, 1136-1147.
41. North, T.E. et al. (2007) Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature, 447, 1007-1011.
42. Prudkin, L. et al. (2009) Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod. Pathol., 22, 668-678.
43. Thomson, S. et al. (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res., 9455-9462.
44. Gitlitz, B. et al. (2012) APRICOT-L: results of a biomarker based phase II randomizedplacebo-controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer (NSCLC) patients. J. Thoracic Oncol., in press.
45. Arnold, S. et al. (2010) Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis. Model Mech., 3, 57-72.
46. Faour, W. et al. (2001) Prostaglandin E2 regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 treated human synovial fibroblasts. J. Biol. Chem., 276, 1720-1731.
47. Masferrer, J.L. et al. (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc. Natl. Acad. Sci., 91, 3228-3232.
48. Yoshinaka, R. et al. COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer. Anticancer Res., 26, 4245-4254.